耐药是影响紫杉类药物临床疗效的重要因素。
Drug resistance is the main restriction factor for clinical usage of taxanes.
目前乳腺癌辅助化疗应用最多的仍是蒽环类及紫杉类药物。
Nowaday, the chemotherapeutic drugs of anthracycline and taxane are used widely in breast cancer.
在2个紫杉类药物中，泰素和泰索帝与阿霉素联合均为合理的选择。
Between the two taxanes, both Taxol and Taxotere are reasonable options to combine with Adriamycin for our patient.
对复发性乳腺癌患者，吉西他滨的疗效则明显优于蒽环类和紫杉类药物（P<0。01）。
Results In primary breast cancer, the antitumor effect of taxane is better than anthracycline and gemcitabine(P <0.01).
患乳腺癌的妇女接受有名的紫杉烷类药物的标准化疗后能实质性的降低复发和死亡的危险。
Women with breast cancer who receive drugs known as taxanes after standard chemotherapy have a substantially reduced risk of recurrence and of death.
然而，知识出这方面的工作可以用于异种生产其他有价值的萜类药物一样，提到青蒿素或紫杉醇。
However, the knowledge out of this work can be applied for the heterologous production of other valuable terpenoid drugs like the mentioned artemisinin or paclitaxel.
紫杉烷类药物具有良好的抗肿瘤活性，然而其极差的水溶性却限制了临床应用。
Taxanes have good antineoplastic activity, but the clinical application has been limited owing to the poor water solubility.
结论含紫杉醇类药物进行术后辅助化疗能增加HER - 2阳性乳腺癌患者无病生存获益，尤其是对ER、PR均阴性且her - 2阳性者。
Conclusions Adjuvant chemotherapy containing paclitaxel can improve the disease-free survival of breast cancer with HER-2 positive, especially for the patients with er and pr negative.
紫杉醇类药物是治疗转移性乳癌的高度活跃的化疗药物。
Taxanes are highly active chemotherapy agents in metastatic breast cancer.
紫杉醇类药物是治疗转移性乳癌的高度活跃的化疗药物。
Taxanes are highly active chemotherapy agents in metastatic breast cancer.
应用推荐